Method for determining responsiveness to CHK1 inhibitors

Details for Australian Patent Application No. 2006215413 (hide)

Owner AstraZeneca AB

Inventors Zabludoff, Sonya; Bergeron, Louise

Agent Davies Collison Cave

Pub. Number AU-B-2006215413

PCT Pub. Number WO2006/087557

Priority 60/654,131 18.02.05 US

Filing date 16 February 2006

Wipo publication date 24 August 2006

Acceptance publication date 7 October 2010

International Classifications

C12Q 1/48 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving transferase

G01N 33/574 (2006.01) Investigating or analysing materials by specific methods not covered by groups - for cancer

G01N 33/68 (2006.01) Investigating or analysing materials by specific methods not covered by groups - involving proteins, peptides or amino acids

Event Publications

6 September 2007 PCT application entered the National Phase

  PCT publication WO2006/087557 Priority application(s): WO2006/087557

7 October 2010 Application Accepted

  Published as AU-B-2006215413

3 February 2011 Standard Patent Sealed

13 September 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006215415-Method for detecting viable cells in a sample by using a virus

2006215406-Amyloid-binding peptides, analogues and uses thereof